3rd ESTRO Forum 2015 dataset will evolve over time as more data become available. Secondly, "classical" trial end points such as overall and progression free survival may not be the most appropriate outcome measures in elderly-specific trials. Given the limited life expectancy, QoL is essential to take into account, and also, cost-effectiveness will be different from the general population. This makes quality adjusted survival, measured in quality adjusted life years (QALYs), a more suitable end point, allowing the answer to both questions: it reflects both the quantity of lifetime gained and the value of this time, and it provides a direct outcome measure to calculate the cost-effectiveness of the treatment. In order to calculate QALYs, utility scores should be collected prospectively. The EuroQoL 5 Dimensions (EQ-5D), a short questionnaire consisting of five questions, is most frequently used for this purpose. General and disease specific quality of life, toxicity and preservation of functional capacity are interesting secondary end points, scored with a uniform and internationally acknowledged scoring system. The additional use of the elderly specific questionnaire EORTC QLQ-ELD15 is recommended, which has recently been validated internationally (Wheelwright, Br J Cancer 2013).
Materials and Methods:
The first clinically deployed online adaptive MR-IGRT system consists of a split 0.35T MR scanner straddling a ring gantry with three MLC-equipped 60 Co heads. The unit is supported by a fast Monte Carlo based treatment planning system allowing real-time adaptive planning with the patient on the table. All patients undergo CT-and MRsimulation for initial treatment planning. A high-resolution volumetric MR image is acquired for each patient at the time of daily treatment setup. Deformable registration is performed using the original simulation CT dataset from initial treatment planning, which allows the transfer of the initial contours and the electron density map to the localization MR of the day. The deformed electron density map is then used to recalculate the original plan on the anatomy of the day for physician evaluation. Physician recontouring and plan re-optimization are performed when required, and patient-specific quality assurance is performed using an independent Monte Carlo calculation for online adaptive QA. The tool also allows for verification of plan parameters against the original plan.
Results: Online adaptive MR-IGRT was implemented in September of 2014. Five patients with abdominopelvic malignancies have been treated with planned evaluation for treatment adaptation in the first 2 months. The clinical setting included neoadjuvant rectosigmoid (n=3), unresectable gastric, and unresectable pheochromocytoma. MR localization images were used to recalculate dose online for all cases. Re-contouring and re-optimization was deemed necessary for 3/5, while the initial plan deemed sufficient for 2/5 cases. Reasons for plan adaptation included change in target size, weight loss, and change in small bowel anatomy. The approximate times required for online dose calculation, re-contouring, re-optimization, and QA were 2, 15, 2, and 5 minutes, respectively. Treatment utilizing the online adaptive plan was completed successfully for all cases when deemed necessary. Conclusions: Online adaptive MR-IGRT has been successfully implemented with planning and QA workflow suitable for routine clinical application. Clinical trials are in development to formally evaluate adaptive treatment of bladder, pancreatic, and oligometastatic abdominal malignancies. Purpose/Objective: Several authors have recommended a 2 mm tolerance for MLC positioning in sliding window treatments. A tolerance of 5mm is typically used in VMAT treatments, but the optimal value for this technique remains unknown. In this paper we present the results of a multicentric study to determine the optimal tolerance for both techniques.
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Materials and Methods:
The procedure used to investigate the optimal tolerance is based on dynalog file analysis. The study was performed with seven Varian linear accelerators (linacs) (Varian Medical Systems, Inc., Palo Alto, CA) from five different centers. All linacs were equipped with dynamic MLCs: six with the Millennium120 model and one with the high definition HD120 model. Dynalogs were collected from over 100,000 clinical treatments and an in-house software was developed for dynalog analysis. By using this software the number of tolerance faults was computed as a function of the user-defined tolerance and the optimal value for this tolerance tolerance -defined as the lowest achievable value-
